Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05977335

Continuous and Non-invasive Measurements by Task Force® CORE/CARDIO in Autonomic Function Testing (AFT)

Background: The investigational device, "Task Force® CORE" (TFC, CNSystems Medizintechnik GmbH, Graz, Austria) together with the "Task Force® CARDIO" (TFCARDIO, CNSystems Medizintechnik GmbH, Graz, Austria) medical device software, is a new CE-marked medical device for continuous non-invasive determination of blood pressure (BP), cardiac output (CO) and derived parameters based on the well established CNAP® (continuous non-invasive arterial pressure) technology by CNSystems.

Aim: The primary aim of this prospective, method comparison, open study is data acquisition for the performance evaluation of the TFC during autonomic function testing in comparison with an clinically accepted reference method. Setting: The setting of the clinical investigation will be the autonomic function testing laboratory at the Department of Neurology, the University Hospital Center Zagreb.

Inclusion criteria: Patients who are over 18 years and who provide written informed consent.

Sample size: The study has an calculated sample size of 70 patients. Considering a drop-out rate of 5%, a total of 75 patients will be included.

Statistics: Descriptive statistics, values for the percentage error and correlation estimates will be derived. Furthermore, scatterplot, Bland-Altman analysis, concordance analysis of parameter changes and further comparative statistics will be performed.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Autonomic Dysfunction Autonomic Nervous System Diseases Nervous System Diseases Neurologic Manifestations Orthostatic Intolerance Pathological Conditions, Signs and Symptoms Primary Dysautonomias Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (patients aged ≥ 18 years)
  • Patients giving written informed consent to participate in the study.
  • Patients with intact perfusion of both hands evidenced by a positive Allen's test.
  • Patients with orthostatic intolerance will be included

Exclusion criteria

  • Patients with vascular implants at the sites of non-invasive BP measurement (fingers or upper arms)
  • Very low perfusion in the periphery
  • Arterial vascular diseases (arteriosclerosis, Raynaud's syndrome, endarteritis obliterans, collagenosis, severely advanced vascular diseases (PAOD))
  • Patients with significant edema in the fingers
  • Patients with atrial fibrillation
  • Patients with valvular disease of grade 2 or above
  • Patients with ventricular assist devices
  • Subjects not passing the Allen's test for both hands.
  • Patients with a large lateral difference in BP (> 15 mmHg for systolic BP and/or >10 mmHg for diastolic BP) or with same arm measurement differences > 10 mmHg in systolic or diastolic BP during assessment of lateral differences

Treatment and study plan

autonomic function testing

Diagnostic Test

Autonomic Function Testing (AFT) includes Valsalva Manoever, Deep Breathing Test, and Head-up Tilt Table Testing.

Primary outcomes

  1. Agreement of blood pressure between investigational and reference device.

    Time frame: The agreement is calculated for the 5 minutes supine baseline period

    The agreement of blood pressure variables [systolic, diastolic and mean pressure in mmHg [millimetres of mercury)] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  2. Agreement of blood pressure between investigational and reference device.

    Time frame: The agreement is calculated for 60 seconds: during (15 seconds) plus after (45 seconds) valsava maneuver

    The agreement of blood pressure variables [systolic, diastolic and mean pressure in mmHg [millimetres of mercury)] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  3. Agreement of blood pressure between investigational and reference device.

    Time frame: The agreement is calculated for 90 seconds Deep Breathing period

    The agreement of blood pressure variables [systolic, diastolic and mean pressure in mmHg [millimetres of mercury)] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  4. Agreement of blood pressure between investigational and reference device.

    Time frame: The agreement is calculated for 10 minutes head-up tilt table test period

    The agreement of blood pressure variables [systolic, diastolic and mean pressure in mmHg [millimetres of mercury)] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  5. Agreement of heart rate between investigational and reference device.

    Time frame: The agreement is calculated for the 5 minutes supine baseline period

    The agreement of heart rate (bpm [beats per minute)] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  6. Agreement of heart rate between investigational and reference device.

    Time frame: The agreement is calculated for 60 seconds: during (15 seconds) plus after (45 seconds) valsava maneuver

    The agreement of heart rate (bpm [beats per minute)] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  7. Agreement of heart rate between investigational and reference device.

    Time frame: The agreement is calculated for 90 seconds Deep Breathing period

    The agreement of heart rate (bpm [beats per minute)] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  8. Agreement of heart rate between investigational and reference device.

    Time frame: The agreement is calculated for 10 minutes head-up tilt table test period

    The agreement of heart rate (bpm [beats per minute)] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  9. Agreement of cardiac output between investigational and reference device.

    Time frame: The agreement is calculated for the 5 minutes supine baseline period

    The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  10. Agreement of cardiac output between investigational and reference device.

    Time frame: The agreement is calculated for 60 seconds: during (15 seconds) plus after (45 seconds) valsava maneuver

    The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  11. Agreement of cardiac output between investigational and reference device.

    Time frame: The agreement is calculated for 90 seconds Deep Breathing period

    The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  12. Agreement of cardiac output between investigational and reference device.

    Time frame: The agreement is calculated for 10 minutes head-up tilt table test period

    The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Chief Technology Officer

CONTACT

[email protected]

00433167234560

Sponsors and collaborators

Lead sponsor

CNSystems Medizintechnik GmbH

Industry

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 4, 2023
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.